This suggests that some of the novel signatures identified in this analysis could also serve as potential biomarkers for the different cancer types, for example: Galectin-7 (encoded by the genes LGALS7, LGALS7B) for squamous cell carcinomas; MUC21 for lung adenocarcinomas, ST3GAL4 for melanomas, MUCL1 for breast cancer (No TNBC), FUT9 for brain cancers, and FUT7 for leukemia (Figure 1C). This evidence concerns the gene LGALS7 and lung adenocarcinoma.